Expensive today but cheaper tomorrow: lifetime costs of an active middle ear implant compared to alternative treatment options
Choosing a treatment option can be a complex medical decision and impose a substantial economic burden for the statutory health insurance. Hence, treatment decisions should be patient-centred at first but also including a shared-decision making on economic feasibility, whether proposed treatment alternatives are likely to be successful and economically reasonable.
Authors
- Steffen Fleßa (ORCID: https://orcid.org/0000-0002-4068-1539)
- Michael Urban (ORCID: https://orcid.org/0000-0002-3328-0091)
- B. Schlick
- Annika Buchholz
- K Kiesewetter
- Cornelia Batsoulis
- Susan H. Busch (ORCID: https://orcid.org/0000-0003-4443-0048)
- Anke Lesinski‐Schiedat (ORCID: https://orcid.org/0000-0003-1057-0245)
- H. Maier (ORCID: https://orcid.org/0000-0001-8457-5327)
- Thomas Lenarz
- Markus Krohn (ORCID: https://orcid.org/0000-0002-9354-1150)
Institutions
- Universitätsmedizin Greifswald (DE)
- Medizinische Hochschule Hannover (DE)
- Universität Greifswald (DE)
- MED-EL (Austria) (AT)
Publication Details
- Journal
- The European Journal of Health Economics
- Published
- 2024-12-06
- DOI
- https://doi.org/10.1007/s10198-024-01743-6
- Citations
- 2
- Primary Topic
- Hearing Loss and Rehabilitation
- Type
- article
- Field-Weighted Citation Impact
- 0.69
Funders
- Universität Greifswald